Texas Institute for Kidney and Endocrine Disorders | Lufkin, TX
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
A Body Mass Index of ≥27.0 kilograms per meter squared (kg/m^2)
Participants may be with or without type 2 diabetes (T2D) unless their hemoglobin A1c (HbA1c) is 10% or lower
Participants have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), as evidenced at least one of the following:
Coronary artery disease
Cerebrovascular disease
Peripheral arterial disease
Chronic kidney disease defined as:
Exclusion criteria
Diabetes related:
CV related:
Participants have any of the following cardiovascular conditions ≤ 90 days prior to randomization:
Have acute decompensated heart failure requiring hospitalization.
Have New York Heart Association (NYHA) Classification Class IV heart failure at screening
Kidney related:
Other medical conditions:
Primary purpose
Allocation
Interventional model
Masking
10,000 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal